Antibiotics for Emerging Pathogens
Antibiotics are organic small molecules, many of which are from natural sources, which are used to treat human infections caused by pathogenic microorganisms. While most validated antibiotics are initially very useful clinically, the pathogenic microorganisms that these compounds target are able to evade the action of the antibiotic by development of resistance mechanisms, which eventually render these antibiotics ineffective. Moreover, these resistance mechanisms can be passed on among different types of bacteria in a very simplistic manner that further compromises the usefulness of antibiotics. As a consequence, many diseases that were thought to have been eradicated by antibiotics (such as tuberculosis) have reemerged within these antibiotic-resistant strains. Hence, there is a constant need for the development of new and better antibiotic molecules that can be used to target these drug-resistant microbial populations.
KeywordsFatty Acid Biosynthesis Trojan Horse Cell Wall Biosynthesis Antibiotic Molecule Fatty Acid Biosynthesis Pathway
A microscopic or submicroscopic organism, too small to be seen by unaided human eye, comprising of bacteria, virus, yeast, protozoa and fungi.
A disease-causing microorganism which may or may not be infectious.
A chemical substance, usually organic in nature, capable of destroying or inhibiting the growth of pathogenic microorganisms.
- Antibiotic resistance
The developed or acquired ability of antibiotic susceptible pathogenic microorganisms to grow and survive despite the inhibitory action of the antibiotic molecules.
Small, linear or circular genetic elements which can replicate independently of the chromosomal DNA inside a cell.
A highly contagious bacterial disease of humans and animals caused by various strains of Mycobacterium, which normally affects the lungs but can also spread to other organs of the body.
A highly contagious protozoal disease caused by various strains of mosquito-borne Plasmodium.
Short chains of amino acids connected by peptide bonds.
Compounds characterized by more than two carbonyl groups connected by single intervening carbon atoms.
Research in the Nair lab is supported by the NIGMS. We thank Neha Garg, Yue Hao, and Zhi Li for stimulating discussions.
- 13.Angulo FJ, Nargund VN, Chiller TC (2004) Evidence of an association between use of anti-microbial agents in food animals and anti-microbial resistance among bacteria isolated from humans and the human health consequences of such resistance. J Vet Med B Infect Dis Vet Public Health 51(8–9):374–379PubMedGoogle Scholar
- 20.Lin L, Ling BD, Li XZ (2009) Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Int J Antimicrob Agents 33(1):27–32PubMedGoogle Scholar
- 45.Okuhara M et al (1980) Studies on new phosphonic acid antibiotics. III. Isolation and characterization of FR-31564, FR-32863 and FR-33289. J Antibiot (Tokyo) 33(1):24–28Google Scholar
- 46.Okuhara M et al (1980) Studies on new phosphonic acid antibiotics. I. FR-900098, isolation and characterization. J Antibiot (Tokyo) 33(1):13–17Google Scholar
- 53.Kurz T et al (2007) Conformationally restrained aromatic analogues of fosmidomycin and FR900098. Arch Pharm (Weinheim) 340(7):339–344Google Scholar
- 66.Yamaguchi H et al (1986) Capuramycin, a new nucleoside antibiotic. Taxonomy, fermentation, isolation and characterization. J Antibiot (Tokyo) 39(8):1047–1053Google Scholar
- 70.Isono F et al (1989) Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity. III. Biological properties. J Antibiot (Tokyo) 42(5):674–679Google Scholar
- 71.Isono F et al (1989) Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity. II. Structural elucidation. J Antibiot (Tokyo) 42(5):667–673Google Scholar
- 72.Inukai M et al (1989) Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity I Taxonomy, fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo) 42(5):662–666Google Scholar
- 111.Wencewicz TA et al (2009) Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin “Trojan Horse” antibiotics and synthetic desferridanoxamine-antibiotic conjugates. Biometals 22(4):633–648PubMedGoogle Scholar